Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 17/20 | 0.82 |
| ▸ | CCND1 | P24385 | 16/20 | 0.82 |
| ▸ | CCND3 | P30281 | 15/20 | 0.82 |
| ▸ | CDK6 | Q00534 | 15/20 | 0.82 |
| ▸ | CDK9 | P50750 | 13/20 | 0.82 |
| ▸ | CDK2 | P24941 | 13/20 | 0.82 |
| ▸ | CDK7 | P50613 | 12/20 | 0.82 |
| ▸ | CCNT1 | O60563 | 11/20 | 0.82 |
| ▸ | CCNH | P51946 | 11/20 | 0.82 |
| ▸ | CCNA2 | P20248 | 11/20 | 0.82 |
| ▸ | CDK1 | P06493 | 10/20 | 0.82 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.82 |
| ▸ | WEE1 | P30291 | 2/20 | 0.78 |
| ▸ | FLT3 | P36888 | 2/20 | 0.78 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.78 |
| ▸ | AURKA | O14965 | 2/20 | 0.78 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.78 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.78 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.78 |
| ▸ | JAK2 | O60674 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30777167 | 1.00 | CDK4 (0.82) | CDK4CCND1CCND3CDK6CDK9 | |
| SCHEMBL18453998 | 0.90 | CDK4 (0.78) | CDK4CCND1CCND3CDK6CDK9 | |
| SCHEMBL29815803 | 0.90 | CDK4 (0.78) | CDK4CCND1CCND3CDK6CDK9 | |
| SCHEMBL30332879 | 0.90 | CDK4 (1.00) | CDK4CCND1CCND3CDK6CDK9 | |
| SCHEMBL20452048 | 0.90 | CDK4 (1.00) | CDK4CCND1CCND3CDK6CDK9 | |
| SCHEMBL20452096 | 0.90 | CDK4 (0.81) | CDK4CCND1CCND3CDK6CDK9 | |
| SCHEMBL29815412 | 0.90 | CDK4 (0.81) | CDK4CCND1CCND3CDK6CDK9 | |
| SCHEMBL18454045 | 0.89 | CDK4 (1.00) | CDK4CCND1CCND3CDK6CDK9 | |
| SCHEMBL18480846 | 0.89 | CDK4 (0.82) | CDK4CCND1CCND3CDK6CDK9 | |
| SCHEMBL29815829 | 0.89 | CDK4 (0.82) | CDK4CCND1CCND3CDK6CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49850-E1 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-RE49850-E1 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-RE49850-E1 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| EP-3957637-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-06-28 | — | — | EP | disclosed |
| EP-3957637-B1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-06-28 | — | — | EP | disclosed |
| EP-3957637-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | Aucentra Therapeutics Pty Ltd (AU) | 2022-02-23 | — | — | EP | disclosed |
| US-20200283431-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| US-20200283431-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2020-09-10 | — | — | US | disclosed |
| US-10479785-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2019-11-19 | — | — | US | disclosed |
| US-10479785-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2019-11-19 | — | — | US | disclosed |
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2018-08-09 | — | — | US | disclosed |
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2018-08-09 | — | — | US | disclosed |
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222900-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDK2 | CDK4 1/4885CCND1 17/4885CCND3 25/4885 |
| US-10479785-B2 | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds | CDK4, CDK6, CDK2 | CDK4 1/4885CCND1 17/4885CCND3 25/4885 |
| US-20200283431-A1 | N-(PYRIDIN-2-YL)-4-(THIAZOL-5-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | CDK4, CDK6, CDKL2 | CDK4 1/4885CCND1 17/4885CCND3 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.